1. [Internet] World Health Organization, Fact sheet N°104. http://www.who.int/mediacentre/factsheets/fs104/en/index.html Accessed Mar 2015.
2. Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmacogenomics Pers Med. 2012;5:89–98.
3. Burman WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers. Am J Resp Crit CareMed. 2001;164:1112–3.
4. Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, Jha B, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010;132:81–6.
5. Tsuyuguchi K, Wada M. Management of adverse effects with antituberculosis chemotherapy [in Japanese]. Kekkaku. 2011;86:87–99.